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ABSTRACT (154 WORDS) 
Nature has produced an intricate machinery to covalently diversify the structure 
of proteins after their synthesis in the ribosome. In an attempt to mimic nature, 
synthetic chemists have developed a large set of reactions that enables post-
expression modification of proteins at pre-determined sites. These reactions are 
now used to selectively install particular modifications on proteins for many 
biological and therapeutic applications. For example, they provide an 
opportunity to install post-translational modifications (PTMs) on proteins to 
dissect their exact biological roles. Labelling of proteins in live cells with 
fluorescent dyes allows to track protein uptake and intracellular trafficking and 
to optically measure physiological parameters. Through the conjugation of 
potent cytotoxics to antibodies, novel anti-cancer drugs with improved efficacy 
and reduced side-effects spectra may be obtained. In this Perspective we 
highlight the most exciting current and future applications of chemical site-
selective protein-modification and consider which hurdles still need to be 
overcome for a more widespread use. 
 
Over billions of years of evolution, nature has developed an intricate machinery 
to covalently attach diverse functional groups to proteins after their synthesis by 
the ribosome, a process called post-translational modification (PTM). Naturally 
occurring protein PTMs are now understood to play important roles in tuning the 
physicochemical properties of proteins, modulating enzymatic activity, 
controlling protein–protein recognition and imparting enzymes with chemical 
functionalities that are not covered by the standard proteinogenic amino acids.1 
For example, the attachment of carbohydrates to proteins — a process known 
as glycosylation — can improve the solubility of proteins and modulate ligand–
receptor interactions.1 Through the reversible addition of phosphate groups at 
serine (Ser), threonine (Thr) or tyrosine (Tyr) residues, enzymes can be 
switched between their active and inactive states. In a similar manner, the 
formation of complexes between two or more proteins can be controlled.1 
Covalently bound co-factors (so-called prosthetic groups) such as flavins or 
inorganic metal clusters can impart metabolic enzymes with the ability to 
perform redox chemistry.1 Collectively, these examples highlight how, through 
the introduction of small modifications, nature often re-designs the structure and 
function of existing proteins to impart immense biological diversity.  
 
In an attempt to follow nature’s example, chemists have developed tools to 
covalently modify proteins with diverse functionalities in the laboratory. Initial 
methodologies typically offered poor control over the precise position of 
modification (i.e., they exhibited poor site-selectivity). Water-stable electrophilic 
carboxylic acid derivatives such as N-hydroxysuccinimidyl (NHS) esters were 
amongst the first reagents used for covalent protein-modification applications.2 
NHS esters react with diverse nucleophiles on protein surfaces, most 
importantly the ε-amine of lysine (Lys) residues. Given the abundance of 
surface Lys on most proteins, the reaction typically results in a mixture of 
products modified at different protein positions. This in turn makes functional 
characterisation of modified proteins difficult, because one is dealing with a 
heterogeneous protein sample rather than a single, homogenous molecule. 
Therefore, reactions that enable chemists to selectively install modifications on 
protein surfaces at pre-defined positions would facilitate both the chemical 
characterization of these modifications and investigation of their exact biological 
function. In the context of this Perspective, we will refer to methods that permit 
the formation of a covalent bond between a protein and a synthetic organic 
molecule at a pre-defined residue as site-selective protein-modification 
reactions. 
 
The challenges associated with the development of site-selective protein-
modification reactions are manifold. Reactions have to be chemoselective for 
one amino acid side chain over all others on the protein surface. Amino acids 
that are lowly abundant on protein surfaces and have unique reactivity lend 
themselves particularly well to site-selective modification chemistries. The most 
important natural amino acid fulfilling these criteria has proven to be surface 
exposed cysteine (Cys) residues.3 Certain natural amino acids may also have 
unique properties when introduced at the N-termini position of a protein. For 
instance, an N-termini serine (Ser) can be oxidized to generate an aldehyde 
that can subsequently be used for site-selective modification.4 Also, at the N-
termini, Cys can react selectively with thioester derivatives to give a native 
peptide bond in a process called native chemical ligation (NCL).5 Site-selective 
protein-modification reactions must furthermore be compatible with aqueous 
buffered systems, not interfere with proper protein folding and proceed at near 
neutral pH and moderate temperatures (i.e., 20-37 °C). Because the chances of 
encountering multiple proteins that carry even lowly abundant natural amino 
acids on their surface increases considerably in complex protein mixtures, it is 
typically only possible to site-selectively label purified recombinant proteins on 
naturally occurring amino acids (Fig. 1). 
 
One method of achieving site-selective modification of a particular protein target 
within a complex mixture of proteins, relies on recent advances in genetic code 
expansion techniques.6,7 These techniques allow for the ribosomal incorporation 
of non-canonical amino acids into proteins that display functionalities which are 
normally not present in living cells.7 These include side chains featuring azide, 
alkyne, ketone, alkene or tetrazine functional groups.8 For each of these 
functionalities, reactions can be envisioned that are highly chemoselective or 
even mechanistically specific for the non-canonical amino acid over all other 
functionalities present in living cells. This concept is referred to as bioorthogonal 
chemistry and is now permitting chemists to site-selectively install modifications 
on individual proteins in complex biological mixtures including in living 
organisms (Fig. 1).9-11 Bioorthogonal ligation reactions may furthermore be 
used on purified protein preparations when bond stability or labelling accuracy 
going beyond that achievable with native amino acids is required (e.g., 
construction of antibody-drug conjugates (ADCs)). 
 
Chemists and biologists are now increasingly using site-selective protein-
modification tools to study the function of naturally occurring PTMs. Additionally, 
by attaching synthetically prepared modifications that are typically not found in 
nature they are attempting to confer novel functionality to proteins of bacterial or 
eukaryotic origin. The aim of this Perspective is to discuss key developments in 
the field of chemical site-selective protein-modification in the context of their 
biological and therapeutic applications, rather than exhaustively present a large 
number of reactions concerning this topic.8,12 The methods covered in this 
Perspective involve ligation reactions between the side-chain of a natural or 
non-canonical amino acid and a suitable small molecule derivative (Fig. 1).  
 
Study of post-translational protein-modifications (PTMs) 
 
Elucidating the effect of PTMs on protein function can greatly be assisted by 
studying pure protein preparations with precise modifications in vitro. Access to 
modified proteins could permit raising modification-specific antibodies,13 
studying enzymatic activities in vitro or potentially affinity-purifying modification-
specific interaction partners from cell lysates, much like established affinity 
purification protocols.14 However, isolation of single isoforms of modified 
proteins from natural sources in sufficient quantities is often challenging. 
Efficient chemical means to prepare proteins with defined PTMs in vitro are thus 
required. Achieving high precision with respect to the site of the modification is 
typically the prime concern. 
 
One approach towards the chemical preparation of post-translationally modified 
proteins that meets the requirement for precision involves the total or semi-
synthesis of proteins with defined PTMs in vitro.5 Typically, peptide fragments 
bearing PTMs are prepared by solid-phase peptide synthesis, joined through 
native chemical ligation (NCL) reactions and are folded in vitro to give the full-
length protein.5 In one example, through the use of NCL, Danishefsky and co-
workers assembled a single glycoform of human erythropoietin with the 
consensus glycosylation motifs placed at their native sites.15 While this 
approach is feasible for relatively short polypeptide chains, it becomes 
excessively cumbersome for large proteins. Alternatively, recombinantly 
expressed protein fragments with N-terminal Cys or C-terminal protein 
thioesters obtained from split-intein fusions can be directly conjugated to small 
peptide fragments using NCL. This technique termed expressed protein ligation 
(EPL)16 is particularly useful, when the modification is relatively close to the N- 
or C-terminus of a protein. EPL has been widely employed by Muir and co-
workers for the study of the effect of histone tail methylation and acetylation on 
chromatin structure and function.17 In one example, a semi-synthetic strategy 
was used to generate a dimethylated arginine (Arg) at position 42 of histone H3. 
Specifically, the sequence from alanine (Ala) 1 to valine (Val) 46 of histone H3 
was prepared by total synthesis and then joined to a recombinantly expressed 
fragment representing Cys 47 to Ala 135 (Fig. 2a). Dimethylation of Arg 42 was 
shown to stimulate transcription in vitro.18 In many other cases, however, PTMs 
are located at sites in the inner regions of the protein, and a totally synthetic or 
semi-synthetic approach for the preparation of the modified protein becomes 
particularly difficult. In such cases, tools that permit the site-selective installation 
of PTMs on fully folded proteins may allow easier access to the desired 
modified protein product. 
 
Site-selective protein-modification chemistry promises to allow the facile 
preparation of proteins with defined PTMs from full-length recombinantly 
produced precursors whilst still meeting the requirement for introducing the 
PTM at a precise position. So far, however, most chemical site-selective 
protein-modification approaches only allow the introduction of PTM mimics. For 
many applications, e.g., raising antibodies, mimics may, however, be fully 
sufficient.19 Davis and co-workers have recently reported a study in which a 
genetically engineered Cys on the surface of kinase p38 was first converted to 
dehydroalanine (Dha) via a bis-alkylation elimination20 procedure with α,α’-di-
bromo-adipyl(bis)amide 1 and subsequently modified via Michael-addition with 
sodium thiophosphate (Fig. 2b) to mimic a native phosphate group.21 In this 
case, the phospho-Cys variant of p38 was sufficiently similar to the natural 
phospho-Tyr to switch the kinase into its active state. The introduction of 
phosphorylated Tyr analogues has also been achieved through the Staudinger-
Phosphite reaction of azides.22 
 
Furthermore, other PTM mimics such as acetylated or methylated Lys, can be 
installed at Dha by reacting the Michael acceptor with a suitable thiol precursor 
(Fig. 2 c).23 Other approaches to prepare histones with thioether mimics of Lys 
methylation and acetylation involve direct Cys alkylation with suitable 
electrophiles,24,25 mixed disulfide formation,26 and radical-initiated thiol-ene 
reactions (Fig. 2c).27 
 
The chemical introduction of native PTMs into full–length proteins at defined 
positions is more difficult, but has found particular success to site-selective 
installation of ubiquitin into recombinant substrate proteins. One strategy 
consisted of site-directed incorporation of a δ-thiol-Lys derivative into a 
recombinant protein that reacts with a C-terminal thioester of ubiquitin through 
NCL; subsequent desulfurization yields a naturally occurring isopeptide bond 
between substrate proteins (e.g., small ubiquitin-like modifier (SUMO)) and 
ubiquitin (Fig. 2d).28 Alternatively, a genetically encoded orthogonal protection 
and activated ligation strategy consisting of genetic encoding of a protected Lys 
residue has been developed. All the other Lys residues present on the protein 
are then chemically protected followed by orthogonal deprotection of the Lys 
that was genetically introduced. The free single Lys then reacts with a C-
terminal thioester of ubiquitin through NCL to yield a natural isopeptide bond. 
Final global deprotection affords the ubiquitinated protein.29 This approach has 
been used to prepare, for example, mono-ubiquitinated human Dvl2 DIX 
domain at Lys54 and Lys58 providing insight into the effect of ubiquitination into 
oligomerization of these domains.30 Protein substrates may contain multiple 
ubiquitin chains. Polyubiquitination of target proteins at specific sites through 
defined chemical linkages has been achieved, for example, by Cu(I)–catalysed 
azide–alkyne cycloaddition-based polymerization of a ubiquitin containing two 
orthogonal non-canonical amino acids which led to the formation of a protease 
resistant polyubiquitinated protein.31 Alternatively, Brik and co-workers have 
introduced suitable electrophiles at the proximal end on ubiquitin for 
chemoselective reaction with a Cys–tagged -globin protein substrate via 
disulfide or thioether bonds.32 
 
To add further complexity, nature often introduces more than one distinct PTM 
at pre–determined sites on a protein. Yet, with all of the abovementioned 
approaches it is currently difficult to site-selectively install two distinct 
modifications in vitro when modifying only natural amino acids. Therefore, 
further work is needed to develop reactions that allow for the facile installation 
of native PTMs on recombinantly produced full-length proteins and the 
installation of two different PTMs on the same protein substrate.  
 
The ability to genetically encode unnatural amino acids into pre-defined sites on 
proteins can help in achieving site-selective protein-modification at multiple 
positions. As an example of such a strategy, Davis and co-workers have built a 
reconstituted and fully functional mimic of P-selectin glycoprotein ligand 1 
(PSGL-1) containing both a sulfo-Tyr mimic and a trisaccharide moiety. This 
was possible through the placement of a Cys residue and an unnatural 
azidohomoalanine (Aha) amino acid which allowed for sequential mixed 
disulfide and Cu(I)-catalysed azide-alkyne cycloaddition reactions on a 
bacterially expressed protein scaffold.33 
 
As a possible alternative, techniques are now emerging which allow for the 
ribosomal incorporation of amino acids that already carry PTMs into proteins.7,34 
These approaches could allow for the expression of precisely post-
translationally modified proteins in living cells and have great potential to 
facilitate the study of PTMs in their native environment. 
 
Site-selective protein-modification for imaging 
 
Modern biology would be impossible without the ability to label biological 
macromolecules with visible light dyes or radionuclides for diverse imaging 
applications. Very often, purified proteins are conjugated to fluorophores or 
radionuclides in vitro and then used to track the localisation of the labelled 
protein or its binding partners in an experimental system in vitro (e.g., 
immunofluorescence) or in vivo (e.g., nuclear imaging techniques). In vitro, site-
selective labelling is not a strict requirement. Labelled protein reagents are 
typically used in excess and non-binding species are removed in washing steps. 
For in vivo applications, on the other hand, it has been shown that the position 
in which a modification is attached to a protein can have an influence on 
pharmacokinetics and biodistribution.35,36 It is so far poorly understood, however, 
how much or if at all site-selectivity would improve the specificity or sensitivity of 
an imaging agent in vivo and further work is required to address this question. 
 
Site-selectivity becomes strictly important when optical imaging techniques are 
used to obtain a more complex functional readout beyond the mere localisation 
of a single protein. For example, measuring the association of two proteins by 
Förster Resonance Energy Transfer (FRET) will require specific placement of 
the FRET donor and acceptor in sites that are not involved in protein-protein 
interaction yet are close enough for FRET to take place. Site-selective labelling 
of purified protein preparations with FRET-dyes can nowadays routinely be 
achieved using commercially available maleimide, sulfone Michael-acceptor 
and haloacetamide reagents in vitro.  
 
Few approaches, however, exist so far to site-selectively label the same protein 
with two different dyes on two different native amino acids.37 Double labelling is 
required if one for example wants to follow conformational changes of a protein 
by FRET. To achieve this aim, it is very often necessary to first introduce an 
unnatural amino acid into the protein of choice that can bioorthogonally react 
with a suitably modified dye. The second label is then site-selectively introduced 
using, for example, the reaction of maleimides with free Cys.38 Alternatively, the 
introduction of two non-canonical amino acids that are suitable precursors for 
protein double-labelling with a FRET pair is now possible using genetic code 
expansion techniques (Fig. 3d).39  
 
Bioorthogonal chemistry also allows for the site-selective labelling of proteins in 
complex mixtures including live cells and animals. Using an electron demand 
inverse Diels–Alder cycloaddition reaction, Chin and co-workers were able to 
site-selectively fluorescently label the non-native amino acid norbornene, which 
was genetically encoded into a protein expressed on the membrane of a 
mammalian cell (Fig. 3a).40 As an additional benefit, fluorophores can also be 
engineered such that their fluorescence markedly increases upon bioorthogonal 
reaction with the protein bearing the unnatural amino acid handle. It is thought 
that this “turn-on” mechanism may give better signal to background ratios than 
those found when labelling proteins with constitutively fluorescent dyes. 
Bioorthogonal labelling of specific proteins may also be used to detail protein 
uptake and internalization in the context of disease. Using an inverse electron 
demand Diels–Alder cycloaddition strategy it was possible to label in a 
quantitative manner anthrax lethal factor (LF) with a small fluorophore.41 This 
enabled the time-lapse monitoring of anthrax LF internalisation and membrane 
translocation processes in living cells. The abovementioned and other recent 
studies8 provide exciting examples of the localisation and tracking of 
bioorthogonally labelled proteins in living cells or in vivo with minimal disruption 
of the native protein and with an unprecedented molecular precision. 
 
Weissleder and co-workers recently extended the use of bioorthogonal 
chemistry on proteins to nuclear imaging applications. They demonstrated that 
a tumour-homing antibody bearing a trans-cyclooctene (TCO) ring on its surface 
could selectively and rapidly react with a radiolabelled variant of a tetrazine ring 
in an inverse electron demand Diels–Alder reaction in vivo in a mouse xenograft 
tumour, thus making the antibody visible in a PET-scanner (Fig. 3b).42 More 
recently, 18F-labeled antibody fragments for positron emission tomography 
(PET) imaging were generated by installing TCO into an anti-Class II MHC 
single domain antibody followed by reaction with a tetrazine-labeled-18F-2-
deoxyfluoroglucose (FDG).43 The method was found to be particularly rapid and 
efficient with a radiochemical yield of >25% enabling imaging of pancreatic 
tumours in vivo with an increased level of specificity compared to conventional 
18F-FDG imaging. Furthermore, Robillard and colleagues used a similar 
approach where, prior to injection of the radiolabelled tetrazine, residual 
amounts of antibody-TCO in circulation were first removed by injection of a 
tetrazine-functionalized clearing agent.44 This led to a significant increase in 
tumour to healthy tissue ratios, and a predicted 8-fold higher tumour dose 
compared with the directly labeled antibody.  Whilst for most protein-
modification reactions that occur in vitro, speed is not the primary objective, the 
extremely fast kinetics of the inverse electron demand Diels–Alder reaction 
makes it particularly suitable for in vivo applications where reagents may rapidly 
be excreted through liver or kidney, however an improved understanding of the 
stability of the trans double bond of TCO that may undergo isomerization in vivo 
will be required. Alternatively, it may also be possible to encode tetrazine motifs 
into the antibody followed by ligation with strained alkene probes avoiding long 
exposure of the trans double bond to in vivo conditions.45 
 
In the coming years, one of the most exciting applications of bioorthogonal 
protein-labelling chemistry may well be the ability to construct functional optical 
sensors to measure diverse physiological parameters inside the dynamic 
environment of living cells and even in animals. For example, Chen and co-
workers have recently described the modification of the acid-sensitive 
chaperone HdeA with an environment-sensitive fluorophore inside the 
periplasm of E. Coli to create a biosensor for extremely low pH values (Fig. 
3c).46 Upon lowering the pH from 7 to 2, HdeA adopts a highly plastic structure 
making hydrophobic residues accessible to the fluorophore, which is reflected in 
an increase in fluorescence. Even bioorthogonal dual modification of a single 
protein with two distinct dyes has recently been achieved. Impressively, Chin’s 
group has developed an optimised translational system for proteins containing 
non-natural amino acids in E. coli that enable the placement of two distinct non-
native amino acids at two pre-determined sites that could be modified with 
mutually and bioorthogonal reactions (Fig. 3d). Site-selective, bioorthogonal 
dual labelling of calmodulin (CaM) with a FRET pair made it possible to follow 
alterations in calmodulin conformation inside the living cell in response to 
changes in Ca2+ concentrations.39  
 
These examples demonstrate that bioorthogonal protein-modification chemistry 
is a very promising tool for the construction of protein biosensors in vivo. Protein 
biosensors have the unique potential to give an optical readout in response to 
physiological changes inside living cells and organisms. These sensors will 
allow biologists to use imaging techniques to study complex processes inside 
living cells and even whole organisms in a spatiotemporally controlled manner. 
 
Modulating the properties of protein therapeutics 
 
Therapeutic proteins are a rapidly growing class of drugs.47 Unfavourable 
pharmacokinetics and immunogenicity, however, often hamper the efficacy of 
recombinant protein therapeutics in vivo. Therapeutic proteins may be quickly 
degraded by proteases or excreted by the kidneys leading to a rapid drop in 
plasma concentration after administration of the drug. A strong immune reaction 
may also be a life threatening complication akin to an allergic shock. 
Alternatively, anti-drug antibodies may inactivate the therapeutic protein and 
lead to treatment resistance. One of the first applications of protein-modification 
chemistry in the context of drug development was the conjugation of protein 
therapeutics with long polyethylene glycol (PEG) chains to extend their plasma 
circulation half-life and attenuate their immunogenicity in vivo.48 By attaching a 
long unstructured polymer chain the hydrodynamic radius of the macromolecule 
is increased thus reducing renal filtration. At the same time, the PEG polymer 
physically shields the protein from degradation by proteases and recognition by 
the immune system. 
 
Many FDA-approved PEGylated protein drugs are still produced using non-site-
selective modification chemistry,49 which can potentially produce inactive 
protein species. Indeed, many marketed PEGylated drugs are less active than 
their unmodified counterparts.50 For this reason, site-selective PEGylation 
should be preferred and site-selective protein-modification chemistry is 
increasingly used for the PEGylating of proteins.51 
 
In one of the first examples of site-selective PEGylation, a N-terminal serine 
residue was oxidized to the corresponding aldehyde using sodium periodate 
followed by subsequent oxime ligation with an aminoxy PEG derivative (Fig. 
4a).4 The modified proteins, interleukin (IL)-8, G-CSF, and IL-1r fully retained 
their activity after PEGylation. Alternatively, Francis and co-workers reported a 
pyridoxal-phosphate (PLP) mediated transamination reaction that introduces 
reactive aldehydes at the N-termini (Fig. 4a).52 In a similar manner, subsequent 
reaction aminoxy-PEG derivative at acidic pH 6.5 provides the corresponding 
oxime product. These methods require however chemical manipulation of the 
N-terminal groups to introduce a reactive aldehyde functionality. More recently, 
the same research group reported a direct site-selective method that enable 
PEGylation of native proteins.53 The method uses 2-pyridinecarboxylaldehydes 
that selective react at the N-termini at neutral pH. The reaction proceeds via the 
formation of the imine followed by the attack of the neighbouring amide nitrogen 
in the protein backbone leading to the formation of a stable imidazolidinone 
conjugate (Fig. 4b). This methodology may be applied to a wide range of native 
proteins with the exception of those where the N-terminus is acylated, those 
with proline in the second position or those where the N-termini are hindered. 
However, in some instances the modification of internal sites on the protein may 
be preferred. Site-selective PEGylation of proteins may also be achieved using 
genetic encoding non-canonical amino acids (ncAA) bearing unique reactive 
handles. Incorporation of para-acetylphenylalanine (pAF) into human growth 
hormone (hGH) followed by reaction with aminooxy-PEG derivatives at pH 6 
enabled the construction of hGH variants with PEG at 20 different pre-
determined sites (Fig. 4c).54 The PEGylated construct of hGH modified at site 
35 demonstrated to possess improved pharmacokinetics in rats and 
comparable efficacy in clinical studies performed in GH-deficient adults but with 
reduced injection frequency. This example is illustrative of the advantage of 
using site-selective PEGylation methods that allow to perform structure-activity 
relationships of modified proteins for optimal pharmacokinetics while retaining 
their biological activity and improving clinical application. 
 
Antibody conjugation for delivery of cytotoxic drugs  
 
More recently, the conjugation of monoclonal antibodies directed against 
tumour marker proteins with highly potent cytotoxic drugs is emerging as a 
strategy to create antibodies with improved killing potential towards malignant 
cells or even turn antibodies lacking any cytotoxic activity into potent 
antineoplastic agents.47 Initial work on antibody-drug conjugates (ADCs) relied 
on poorly site-selective conjugation strategies to attach drugs to antibodies 
yielding a heterogeneous mixture of antibodies with different drug loading at 
different sites.55-57 
 
It was soon found that both the number of drugs per antibody and the 
attachment site could have a profound effect on the pharmacokinetics, efficacy 
and toxicity of an ADC.36,58 A high ratio of drug to antibody (typically > 2) may 
lead to reduced thermostability of the ADC56 and result in a faster clearance 
from the bloodstream.57 ADCs with high drug to antibody ratio (DAR) were also 
found to have a smaller therapeutic window than ADCs with low DARs.57 
Additionally the site of drug attachment can have a profound effect on clearance 
kinetics and off-target ADC toxicity36,58 as well as in plasma stability and 
efficacy.59 These observations demonstrate the importance of using site-
selective protein-modification chemistries for the synthesis of homogenous 
protein conjugate therapeutics. 
 
Currently, the most commonly used approach for the site-selective generation 
of antibody-conjugate therapeutics is the Michael-addition reaction of the thiol 
side-chain of genetically engineered Cys residues on the antibody’s surface 
with maleimides (Fig. 5a).3 Protocols have been established which allow for the 
selective reduction of engineered Cys whilst leaving native disulfide bonds on 
the antibody intact.36 Using carefully optimized conditions, ADC preparations 
containing >90% ADCs with exactly two drugs per antibody could be 
prepared.36 
 
A potential drawback of maleimide chemistry is related to the fact that the 
thioether bond formed between the protein’s Cys and the maleimide may not be 
fully stable in plasma (Fig. 5a).58 Conjugates can undergo a retro-Michael 
addition releasing the maleimide from the carrier protein under physiological 
conditions.60 In the case of ADCs, the product of this reaction would be a highly 
potent cytotoxic drug that can kill cells in healthy tissues. Indeed, off-target 
toxicity is a pressing problem in the clinical development of ADCs. Different 
strategies have thus been pursued to improve the stability of maleimide 
conjugates. Conjugation sites have been placed in close proximity to positively 
charged amino acid residues, which promote the hydrolysis and ring-opening of 
maleimides to give more stable species.58 Linkers containing primary amines in 
close proximity to a malemide that undergo rapid hydrolysis to the more stable 
ring-opened form have also been proposed (Fig. 5a).61,62 The resulting ADCs 
were demonstrated to be more stable in plasma and more efficacious in vivo 
while reducing the side effects observed when using traditional maleimides. 
 
A number of reactions for the modification of Cys that inherently give more 
stable thioether bonds, such as the Julia–Kocienski type modification developed 
by Barbas and co-workers (Fig. 5a)63 or the Michael-addition of thiol 
nucleophiles to Dha developed by Davis and co-workers (Fig. 5a),64 may also 
be exploited for the synthesis of ADCs. These technologies are fairly novel, 
however, and we are not aware of any industrial ADC discovery programs using 
them thus far. 
 
As an alternative to the chemical modification of genetically incorporated Cys 
residues on monoclonal antibody (mAb) surfaces, one can incorporate 
unnatural amino acids into mAbs and modify them using bioorthogonal 
reactions. This approach has the potential advantage of yielding highly 
homogeneous protein conjugate preparations and antibody-drug linkages with 
high stability.  
 
Schultz and co-workers have genetically incorporated para-acetylphenylalanine 
(pAF) into mAbs and reacted the side chain ketone with an aminoxy-modified 
version of the potent cytotoxic drug monomethyl auristatin E (MMAE) 3 for the 
preparation of ADCs (Fig. 5b i).65 The same antibody was expressed with two 
Cys in the same positions as the pAF and conjugated with a maleimide-
containing version of MMAE. The pAF-modified ADC had a drug-to-antibody 
ratio (DAR) of exactly 2.0 whereas attempts to selectively modify the two 
genetically introduced Cys on the mAb using a maleimide-containing derivative 
of MMAE gave a DAR of 2.3. The homogenous pAF-modified ADCs were found 
to be more stable than conventional maleimide linkages in vivo.66 These 
characteristics resulted in an improved efficacy of the bioorthogonally-modified 
ADC in xenograft-tumour-bearing mice. 
 
Bertozzi and co-workers have reported a site-selective protein-ligation where 
aldehyde-containing proteins rapidly react with 3-methylhydroxylamino indoles 
in a Pictet–Spengler type mechanism.67 A variation of the methodology, the 
hydrazino-iso-Pictet–Spengler (HIPS) ligation, yields highly stable C–C linkages 
between aldehyde-containing antibodies and drugs containing 3-
methylhydrazino indole-groups 4 (Fig. 5b ii). As such, this methodology has 
been used for the construction of ADCs.68 By performing HIPS conjugations at 
different locations on an IgG1 backbone, it was shown that the site of 
conjugation influences dramatically the in vivo efficacy and pharmacokinetic 
parameters.68 In addition, the stable conjugates built using HIPS conjugation 
strategy exhibited an improved safety profile in rats when compared with those 
conjugates prepared using a non-site-selective lysine conjugation strategy.  
 
Collectively, these observations highlight the fact that site-selective protein-
conjugation reactions can vastly improve the therapeutic efficacy of protein-
conjugate therapeutics when compared to protein conjugates that were 
synthesised using non-selective bioconjugation chemistry, at least within animal 
models of disease. Although clinical proof is not likely within the next few years, 
we expect that protein conjugate therapeutics synthesised using site-selective 
modification reactions that yield homogenous and more stable products will also 
be more efficacious and tolerable to patients than currently used heterogeneous 
and potentially unstable conjugates. 
 
The future of bioorthogonal chemistry on protein surfaces 
 
Evidence is now accumulating that chemistry on protein surfaces will in the 
future go far beyond bioconjugation. In particular the combination of genetic 
code expansion for the incorporation of non-canonical amino acids into proteins 
with bioorthogonal chemistry could enable tantalizing new applications. For 
example, the genetic incorporation of caged amino acids that can be 
deprotected using bioorthogonal reactions holds great potential for the precise 
spatiotemporal control of protein function in vivo. Indeed, a palladium-mediated 
depropargylation has recently been achieved within a living cell and could be 
used to restore the function of a propargyl-protected protein (Fig. 6a).69 In 
another example, a tetrazine-triggered protein decaging method based on the 
inverse electron-demand Diels–Alder reaction was successfully employed for 
the bioorthogonal deprotection of a caged Lys within living cells (Fig. 6b).70 The 
inverse electron-demand Diels–Alder reaction elimination occurs through the 
conversion of the dihydropyridazine adduct, formed from the [4+2] cycloaddition 
between a 1,2,4,5-tetrazine and TCO, to a pyridazine with elimination of CO2 
and an amine derivative. 
 
This inverse electron demand Diels–Alder elimination reaction also was used by 
Robillard and co-workers in a small molecule pro-drug strategy. A carbamate 
between 1-hydroxy-trans-cyclooctene (HO-TCO) and the amino sugar of 
doxorubicin (DOXO), a chemotherapeutic agent commonly used for the 
treatment of cancer, was prepared.71 When reacting the DOXO derivative with a 
tetrazine reagent in an inverse electron demand Diels-Alder fashion, the 
dihydropyridazine product undergo conversion into a conjugated pyridazine with 
consequent elimination of the NH2-substituted DOXO and CO2.
71 It remains to 
be demonstrated that this strategy can be expanded to antibodies for in vivo 
bioorthogonal elimination and delivery of drugs. For example, by incorporating a 
DOXO HO-TCO carbamate to a tumour-homing antibody, one could selectively 
transport the inactivated drug into the tumour and release it selectively by 
injecting tetrazine as a trigger substance. This in turn would decrease exposure 
of healthy tissues to DOXO and reduce treatment-associated side effects. 
Bioorthogonal chemistry on protein surfaces may thus permit the development 
of novel medicines with a spatially and temporally defined action for the 
treatment of cancer and other debilitating diseases. 
 
Alternatively, genetic encoding of photocaged variants of natural amino acids 
(e.g., Cys and Tyr) could be used to the same aim. In one case, 
photodeprotection of photocaged Cys results in rapid activation of TEV protease 
within living cells in their native environment (Fig. 6c).72 Similarly, deprotection 
of a key photocaged Tyr residue was used to control phosphorylation and signal 
transduction.73 It will emerge over the coming years how far and in which 
settings these techniques are superior to currently used methods for the control 
of protein function, for example, at the transcription level with doxocyclin 
inducible promoters, and for in situ pro-drug antibody-based delivery strategies. 
 
Conclusions and outlook 
 
Site-selective protein-modification chemistry can enable the in vitro and in vivo 
study of PTMs, construction of protein-based sensors for biological applications 
or the preparation of powerful new protein therapeutics. Other applications that 
were not addressed in detail here may be found in the fields of material 
sciences or regenerative medicine where the synthesis of chemically defined 
scaffolds containing protein building blocks (e.g., factors for cell attachment and 
growth) may play an important role.  
 
Site-selective protein-modification chemistry comes in two flavours: reactions 
with naturally occurring but lowly abundant amino acids is typically limited to the 
modification of isolated proteins in vitro. Methods that allow the modification of 
proteins with diverse synthetic molecules ranging from PTMs or their mimics to 
fluorophores and drugs with high accuracy with respect to the site of 
modification are now available.  The use of low reagent’s concentration and the 
stability of the bond between protein and the modification are primary concerns 
for the modification of proteins in vitro (e.g., for ADCs) and methods that satisfy 
this requirement are now becoming available. The advantage of modifying 
naturally occurring amino acids lies in the fact that standard methods of protein 
engineering can be easily employed to generate the protein starting material.  
 
Bioorthogonal ligation reactions, on the other hand, are a type of site-selective 
protein-modification chemistry directed at unnatural functionalities introduced 
into pre-determined sites on proteins often using genetic code expansion 
techniques. Bioorthogonal ligation reactions are generally more versatile than 
classical site-selective protein-modification reactions directed at natural 
proteinogenic amino acids. In particular, bioorthogonal ligation chemistry may 
allow for the site-selective modification of proteins even in complex protein 
mixtures, where rare amino acids traditionally used for site-selective protein-
modification (i.e., most commonly Cys) are present in multiple copies. It now 
even allows for the site-selective modification of individual proteins in cells and 
living organisms where high reaction speeds on top of high selectivity may be 
required.  
 
Bioorthogonal protein-modification chemistry may also be particularly suited to 
site-selectively introduce two or even more modifications on the same protein 
opening new doors to interrogate protein structure, dynamics and function in 
their native environment. The main drawback of bioorthogonal approaches 
remains the need for introducing non-natural amino acids into the target protein 
prior to modification but efficient methods even for the large-scale production of 
proteins incorporating non-native amino acids are now becoming available.66,74 
Together with efforts to integrate optimised genetic encoding expression 
systems for researchers including the Unnatural Protein Facility, located at 
Oregon State University (OSU),75 such techniques will hopefully find increased 
implementation in laboratories.  
 
Modern site-selective, bioorthogonal protein-modification techniques have 
shown potential to provide molecular insights in numerous proof-of-concept 
studies and enabled the construction of more efficient and safer protein 
therapeutics. As the number of reactions at our disposal for the site-selective 
and bioorthogonal modification of proteins increases, we anticipate that the 
widespread use of bioorthogonal protein-modification will generate fundamental 
new basic biology knowledge, imaging and therapeutic applications with 
unprecedented precision. It is, however, key to make these methodologies 
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Figure 1. Conceptual strategy to achieve site-selective protein-
modification using biocompatible chemical reactions in vitro and in vivo. 
Typically, site-selective chemical modification of proteins can be achieved either 
i) on a natural amino acid side chain with unique reactivity (e.g., Cys) of which a 
single copy is already present on the protein of interest or may be introduced by 
site-directed mutagenesis or ii) on a non-canonical amino acid featuring a side 
chain with a functional group that is normally not present in living systems but 
can be introduced using genetic encoding procedures (e.g., azide, alkyne, 
ketone, alkene, tetrazine). In the case of natural amino acid side chains, one is 
limited to the modification of purified proteins in a test tube as many other 
biomolecules may display the same functionality in a complex protein mixture. 
Using non-canonical amino acids, on the other hand, one can devise reactions 
that are selective over all naturally occurring amino acid side chains thus 
permitting site-selective modification of individual proteins in complex mixtures 
and living organisms. Upon choice of the functionality to be chemically targeted, 
reaction with a suitable modified molecule of interest (e.g., PTM, fluorescent 
label or cytotoxic drug) must proceed in a chemoselective manner under 
physiological conditions. 
 
Figure 2. Chemical site-selective installation of PTMs at pre-determined 
sites on proteins. a, A semi-synthetic strategy for the generation of a histone 
protein with a dimethylated Arg residue at position 42. Briefly, histone 
H3R42Me2 was assembled from two synthetic fragments and one recombinant 
fragment through the use of NCL and EPL. The final step involves selective 
radical-mediated desulfurization of the two Cys residues at the ligation sites into 
the native Ala residues to give the final semi-synthetic H3R42Me2. b, Site-
selective installation of a phosphorylation mimic in the activation loop of protein 
kinase p38α. This was achieved by replacing the native Tyr residue with a Cys 
residue, which was subsequently chemically converted into Dha. Michael-
addition of sodium thiophosphate enables access to a fully functional synthetic 
phospho-Cys mimic capable of switching the kinase to an active state. c, 
Chemical installation of thioether mimics of acetylated or methylated Lys at pre-
determined sites on histone proteins for the study of genetic regulation. 
Chemically defined PTMs can be achieved directly on Cys by alkylation with 
suitable electrophiles, mixed disulfide formation or radical-initiated thiol-ene 
reactions. Alternatively, Cys can be converted to Dha followed by Michael-
addition of suitable nucleophiles. Through this strategy, it is possible to create 
fully functional mimics of PTMs on histone proteins. d, Combined genetic code 
expansion with traceless NCL for the formation of isopeptide linked ubiquitin 
and protein substrates.  
 
Figure 3. Bioorthogonal protein-modification chemistry for live cell 
imaging applications. a, Genetic encoding of a norbornene amino acid into a 
mammalian cell-surface protein followed by selective labelling with a tetrazine-
modified version of the fluorescent dye TAMRA-X. b, Trans-cyclooctyne (TCO) 
was conjugated to a tumour-homing antibody and injected into a tumour-bearing 
mouse. Once the antibody had accumulated inside the tumour and cleared from 
healthy organs, a radiolabelled tetrazine was injected. The tetrazine and TCO 
rapidly reacted leading to retention of radioactivity at the tumour site that could 
be visualized by radio-imaging approaches. c, Encoding of an azido-amino acid 
into the acid-sensitive chaperone HdeA inside the E. coli periplasm. 
Bioorthogonal attachment of an alkyne derivative of the environmentally 
sensitive dye 4-N,N-dimethylamino-1,8-naphthalimide (4-DMN) to the protein 
was achieved using Cu(I)-catalyzed azide-alkyne cycloaddition. Upon pH 
dependent conformational changes in HdeA, 4-DMN changes its fluorescence 
properties enabling the measurement of changes in local pH. d, Simultaneous 
genetic encoding of two distinct non-natural amino acids into the same protein. 
The tetrazine and norbornene amino acids did not react with each other but the 
tetrazine selectively reacted with a strained cyclooctyne ring and the 
norbornene with a different tetrazine. This mutually orthogonal and 
bioorthogonal pair of reactions allowed for the site-selectively placement of two 
distinct fluorescent dyes onto the surface of calmodulin in E. coli and measure 
its conformational changes in response to Ca2+ stimuli by FRET.  
 
Figure 4. Example of strategies to achieve site-selective PEGylation of 
proteins. a, Examples of PEGylation of the N-termini using oxime ligation. N-
terminal aldehydes can be either generated through oxidation using sodium 
periodate or using pyridoxal-phosphate (PLP) promoted transamination. 
Subsequent oxime ligation with aminoxy PEG derivatives afford the N-terminally 
PEGylated protein. b, Site-selective attachment of 2-pyridinecarboxylaldehydes 
PEG derivatives to native proteins at neutral pH. c, Genetic encoding of pAF 
into hGH at pre-determined site 35 followed by oxime ligation with a aminoxy 
PEG derivative at acidic pH. 
 
Figure 5. Site-selective protein-modification reactions for the synthesis of 
antibody-drug conjugates (ADCs). a, Reactions selective for Cys. The 
classical chemoselective reaction of maleimides with thiols is widely used for 
the site-selective synthesis of ADCs. The initial product of the reaction is now 
known to be unstable and can either regenerate the starting materials through a 
retro-Michael addition or hydrolyze to form the more stable ring-opened product. 
Ring opening can be facilitated by placing a positively charged amino acid in 
close vicinity to the modified Cys on the protein surface. Alternatively, a primary 
amine can be placed next to the maleimide on the linker between drug and 
antibody. Conversion of Cys into Dha on protein surfaces using 1 followed by 
Michael-addition with thiol-containing drugs results in a very stable thioether 
bond. Similarly, the Julia–Kocienski-type reaction of a protein surface Cys with 
a methylsulfonylbenzothiazole reagent 2 yields a site-selective protein 
conjugation product that is intrinsically very stable in plasma and may be very 
useful for the synthesis of ADCs. b, Bioorthogonal reactions selective for non-
natural amino acids. i, Genetically introduced pAF on the antibody surface can 
selectively react with hydroxylamine-containing drugs 3 to form a very stable 
linkage. ii, Genetically or enzymatically introduced aldehydes on the antibody 
surface can selectively react with 4 in a Pictet–Spengler type reaction to form a 
very stable ADC. 
 
Figure 6. Bioorthogonal approaches to in situ protein activation. a, A 
biocompatible palladium catalyst that cleave the propargyl carbamate group of a 
protected Lys analogue to generate a free lysine was used to modulate the 
function of an intracellular protein in a gain-of-function fashion. b, A TCO-caged 
Lys on the active site of a protein renders the protein inactive. Upon reaction 
with 3,6-dimethyl-1,2,4,5-tetrazine, rapid inverse electron demand Diels–Alder 
elimination took place enabling bioorthogonal decaging and intracellular 
activation of the protein target in its native cellular context. c, Photodeprotection 
of a caged Cys that was genetically encoded into TEV to reveal the native 
protein in live cells. 
